Rola VEGF, czynnika neurotroficznego i proangiogennego w patogenezie choroby Alzheimera

• Authors: Marta Nowacka , Ewa Obuchowicz

Title variants

EN

Role of VEGF, neurotrophic and proangiogenic factor in pathogenesis of Alzheimer’s disease

• Languages of publication: PL

Abstracts

PL

Choroby neurodegeneracyjne należą do najpoważniejszych schorzeń, z jakimi zmaga się obecnie medycyna. Wydaje się, iż obserwowany wzrost częstości występowania choroby Alzheimera w dużej mierze wiąże się z ogólnym starzeniem się ludzkiej populacji. Mimo intensywnych badań prowadzonych od kilkudziesięciu lat etiopatogeneza tej choroby nie jest poznana, nie znamy również leku, który przynajmniej hamowałby skutecznie postęp tej choroby. Naczyniowo-śródbłonkowy czynnik wzrostu (vascular endothelial growth factor, VEGF) jest dobrze scharakteryzowanym czynnikiem proangiogennym, niezbędnym do powstawania nowych naczyń krwionośnych zarówno podczas rozwoju zarodkowego, jak i w warunkach patologicznych. Badania przeprowadzone w ostatnich latach wskazały na nową rolę VEGF jako czynnika neurotroficznego. Podczas rozwoju układu nerwowego VEGF odgrywa kluczową rolę nie tylko w różnicowaniu i tworzeniu sieci naczyń w rozwijającym się mózgu, lecz także w proliferacji neuronów oraz w kierowaniu procesem rozwoju neuronalnego. Obecnie uważa się, że VEGF jako czynnik proangiogenny i neurotroficzny prawdopodobnie bierze udział w patogenezie choroby Alzheimera. U osób cierpiących na tę chorobę stwierdzono nieprawidłową regulację ekspresji VEGF. Zarówno w badaniach in vitro przeprowadzonych na hodowlach komórkowych, jak i w badaniach in vivo na zwierzęcych modelach transgenicznych stwierdzono występowanie interakcji między VEGF a b-amyloidem. Te przesłanki zainspirowały badaczy do podjęcia badań nad ewentualnym wykorzystaniem farmakologicznej modulacji VEGF w terapii choroby Alzheimera.

EN

Currently, neurodegenerative disorders represent one of the most serious diseases the mankind is struggling with. An increased morbidity rate of Alzheimer’s disease seems to be associated with general population aging. Despite the fact that the intensive studies have been conducted in many research centres for several years, etiopathogenesis of Alzheimer’s disease is still not fully understood. Furthermore, there is no drug which could, at least, inhibit progress of this disease effectively. Vascular endothelial growth factor (VEGF) is well-characterized proangiogenic substance, essential for the formation of new blood vessels during embryogenesis as well as others pathological condition. Recently, a new role for VEGF as a neurotrophic factor has been emerged. In the developing nervous system, VEGF plays a pivotal role in neuronal proliferation and guidance of neuronal development process. As proangiogenic and neurotrophic factor, VEGF has been suggested to be involved in the pathogenesis of Alzheimer’s disease. In patients suffering fromthis disease patients abnormal regulation of VEGF expression have been reported. Moreover, an interaction between VEGF and b-amyloid has been evidenced in in vitro studies on cell cultures and in vivo studies conducted on transgenic lab animals. In consequence, these data have stimulated an increasing interest in assessing the therapeutic potential of VEGF pharmacological modulation in treatment of Alzheimer’s disease.

Keywords

EN

Alzheimer’s disease; b-amyloid; choroba Alzheimera; leczenie; modele transgeniczne choroby Alzheimera; naczyniowo--śródbłonkowy czynnik wzrostu (VEGF); transgenic models; treatment of AD; vascular endothelial growth factor (VEGF)

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Aktualności Neurologiczne
• Year: 2011
• Volume: 11
• Issue: 2
• Pages: 123-130

Contributors

author

Marta Nowacka

• Zakład Farmakologii Katedry Farmakologii Śląskiego Uniwersytetu Medycznego

author

Ewa Obuchowicz

• Zakład Farmakologii Katedry Farmakologii Śląskiego Uniwersytetu Medycznego

References

• 1. Castellani R.J., Rolston R.K, Smith M.A.: Alzheimer disease. Dis. Mon. 2010; 59: 484-546.
• 2. Sommer B.: Alzheimer’s disease and the amyloid cascade hypothesis: ten years on. Curr. Opin. Pharmacol. 2002; 2: 87-92.
• 3. Hardy J., Selkoe D.J.: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
• 4. Tanzi R.E., Moir R.D., Wagner S.L.: Clearance of Alzheimer’s Ab peptide: the many roads to perdition. Neuron 2004; 43: 605-608.
• 5. Yang S.P., Bae D.G., Kang H.J. i wsp.: Co-accumulation of vascular endothelial growth factor with b-amyloid in the brain of patients with Alzheimer’s disease. Neurobiol. Aging 2004; 25: 283-290.
• 6. Tarkowski E., Issa R., Sjögren M. i wsp.: Increased intrathecal levels of the angiogenic factors VEGF and TGF-b in Alzheimer’s disease and vascular dementia. Neurobiol. Aging 2002; 23: 237-243.
• 7. Brockington A., Lewis C., Wharton S., Shaw P.J.: Vascular endothelial growth factor and the nervous system. Neuropathol. Appl. Neurobiol. 2004; 30: 427-446.
• 8. Carmeliet P., Storkebaum E.: Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 2002; 13: 39-53.
• 9. Ruiz de Almodovar C., Lambrechts D., Mazzone M., Carmeliet P.: Role and therapeutic potential of VEGF in the nervous system. Physiol. Rev. 2009; 89: 607-648.
• 10. Wick A., Wick W., Weltenberger J. i wsp.: Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J. Neurosci. 2002; 22: 6401-6407.
• 11. Sun Y., Jin K., Xie L. i wsp.: VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 2003; 111: 1843-1851.
• 12. Manoonkitiwongsa P.S., Schultz R.L., McCreery D.B. i wsp.: Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J. Cereb. Blood Flow Metab. 2004; 24: 693-702.
• 13. Storkebaum E., Carmeliet P.: VEGF: a critical player in neurodegeneration. J. Clin. Invest. 2004; 113: 14-18.
• 14. Bartoszewska M.: Molekularne mechanizmy choroby Alzheimera. Postępy Biol. Kom. 2008; 35: 333-350.
• 15. de la Torre J.C.: Pathophysiology of neuronal energy crisis in Alzheimer’s disease. Neurodegener. Dis. 2008; 5: 126-132.
• 16. Isingrini E., Desmidt T., Belzung C., Camus V.: Endothelial dysfunction: a potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer’s disease? Curr. Opin. Investig. Drugs 2009; 10: 46-55.
• 17. Kalaria R.N.: Cerebral vessels in aging and Alzheimer’s disease. Pharmacol Ther. 1996; 72: 193-214.
• 18. Perlmutter L.S., Chui H.C., Saperia D., Athanikar J.: Microangiopathy and the colocalization of heparin sulfate proteoglycan with amyloid in senile plaques of Alzheimer’s disease. Brain Res. 1999; 508: 13-19.
• 19. Kalaria R.N.: Vascular factors in Alzheimer’s disease. Int. Psychogeriatr. 2003; 15 supl. 1: 47-52.
• 20. Chiappelli M., Borroni B., Archetti S. i wsp.: VEGF gene and phenotype relation with Alzheimer’s disease and mild cognitive impartment. Rejuvenation Res. 2006; 9: 485-493.
• 21. Girouard H., Iadecola C.: Neurovascular coupling in the normal brain and in hypertension, stoke, and Alzheimer disease. J. Appl. Physiol. 2006; 100: 328-335.
• 22. Mawuenyega K.G., Sigurdson W., Ovod V. i wsp.: Decreased clearance of CNS b-amyloid in Alzheimer’s disease. Science 2010; 330: 1774.
• 23. Zlokovic B.V.: Neurovascular mechanism of Alzheimer’s neurodegeneration. TRENDS Neurosci. 2005; 28: 202-208.
• 24. de la Torre J.C.: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152-1162.
• 25. Miao J., Xu F., Davis J. i wsp.: Cerebral microvascular amyloid b protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid b precursor protein. Am. J. Pathol. 2005; 167: 505-515.
• 26. Kalaria R.N., Cohen D.L., Premkumar D.R.D. i wsp.: Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Mol. Brain Res. 1998; 62: 101-105.
• 27. Solerte S.B., Ferrari E., Cuzzoni G. i wsp.: Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer’s disease: recovering effect with insulin and DHEA sulfate. Dement. Geriatr. Cogn. Disord. 2005; 19: 1-10.
• 28. Mateo I., Llorca J., Infante J. i wsp.: Low serum VEGF levels are associated with Alzheimer’s disease. Acta Neurol. Scand. 2007; 116: 56-58.
• 29. Yang S.P., Kwon B.O., Gho Y.S., Chae C.B.: Specific interaction of VEGF165 with b-amyloid, and its protective effect on b-amyloid-induced neurotoxicity. J. Neurochem. 2005; 93: 118-127.
• 30. Del Bo R., Ghezzi S., Scarpini E. i wsp.: VEGF genetic variability is associated with increased risk of developing Alzheimer’s disease. J. Neurol. Sci. 2009; 283: 66-68.
• 31. Del Bo R., Scarlato M., Ghezzi S. i wsp.: Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann. Neurol. 2005; 57: 373-380.
• 32. Chapuis J., Tian J., Shi J. i wsp.: Association study of the vascular endothelial growth gene with risk of developing Alzheimer’s disease. Neurobiol. Aging 2006; 27: 1212-1215.
• 33. Mateo I., Llorca J., Infante J. i wsp.: Case-control of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer’s disease. Neurosci. Lett. 2006; 401: 171-173.
• 34. Patel N.S., Mathura V.S., Bachmeier C. i wsp.: Alzheimer’s b-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J. Neurochem. 2010; 112: 66-76.
• 35. Bürger S., Noack M., Kirazov L.P. i wsp.: Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and b-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int. J. Dev. Neurosci. 2009; 27: 517-523.
• 36. Bürger S., Yafai Y., Bigl M. i wsp.: Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the b-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice. Int. J. Dev. Neurosci. 2010; 28: 597-604.
• 37. Lopez-Lopez C., Dietrich M.O., Metzger F. i wsp.: Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer’s disease. J. Neurosci. 2007; 27: 824-831.
• 38. Spuch C., Antequera D., Portero A. i wsp.: The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease. Biomaterials 2010; 31: 5608-5618.

• Document Type: article